BeOne Medicines' BRUKINSA combination therapy for mantle cell lymphoma receives FDA priority review designation
ONC BeOne Medicines Ltd ADR
$417.33 +2.55%
View chart & analysis → - 1BeOne Medicines received FDA acceptance of its supplemental New Drug Application for the combination of BRUKINSA and rituximab and was granted priority review designation.
- 2The MANGROVE clinical trial demonstrated a 43% reduction in the risk of disease progression or death compared to bendamustine and rituximab combination therapy.
- 3Amit Agarwal, Chief Medical Officer of Hematology at BeOne Medicines, said this regulatory development could provide an alternative to chemotherapy-based treatments for newly diagnosed patients.
So what's the key point?
The FDA has agreed to fast-track the review of a new treatment from BeOne Medicines. This therapy reduces disease risk by 43% and could offer a new treatment option for patients.
Source InvestorsHub +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.